Taro Pharmaceutical Industries Ltd. Ordinary Shares (NYSE: TARO)
On April 15, 2024, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omitted material information with respect to the Proposed Transaction, rendering the Proxy Statement false and misleading. Specifically, the Complaint alleges the Proxy contained materially incomplete and misleading information concerning BofA Securities, Inc.’s methodology and key assumptions in describing the valuation analyses that BofA Securities performed.